The White House is expected to announce on Tuesday (30) the launch of TrumpRx, a sales portal for medications aimed at the end consumer, according to information published by the Wall Street Journal. The project also includes a partnership with Pfizer, which has committed to reducing the prices of some of its medications in the United States.
President Donald Trump will participate in the official announcement, accompanied by the pharmaceutical company’s CEO. The site will allow American citizens to buy medications directly from a government-administered portal, paying cash for certain products. Prices would be reduced through negotiations conducted by the federal administration itself. It is still unclear how many and which medications will be part of the platform, nor whether it will truly be advantageous for the majority of the population, already covered by private health plans, Medicare, or Medicaid.
The initiative represents another step by the White House in attempting to tackle the high costs of the U.S. pharmaceutical industry, a recurring theme in public debate that generates strong political pressure. The presence of Pfizer’s CEO at the announcement reinforces the intention to show industry support for the project.
Despite the expectation surrounding the promise of discounts, health experts note that the measure may have limited reach. This is because a significant portion of consumers already has insurance coverage, which may reduce the attractiveness of TrumpRx as a purchasing alternative.
The official announcement will provide more details about the site’s operation and the conditions agreed with Pfizer, a company that holds a prominent position in the global medications market.
Source: www.brasil247.com